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Objectives
There are currently few data on the long-term risk of cancer and death in individuals taking
raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association.
Methods
The EuroSIDA cohort was divided into three groups: those starting RAL-based combination
antiretroviral therapy (cART) on or after 21 December 2007 (RAL); a historical cohort (HIST) of
individuals adding a new antiretroviral (ARV) drug (not RAL) to their cART between 1 January
2005 and 20 December 2007, and a concurrent cohort (CONC) of individuals adding a new ARV
drug (not RAL) to their cART on or after 21 December 2007. Baseline characteristics were
compared using logistic regression. The incidences of newly diagnosed malignancies and death
were compared using Poisson regression.
Results
The RAL cohort included 1470 individuals [with 4058 person-years of follow-up (PYFU)] compared
with 3787 (4472 PYFU) and 4467 (10 691 PYFU) in the HIST and CONC cohorts, respectively. The
prevalence of non-AIDS-related malignancies prior to baseline tended to be higher in the RAL
cohort vs. the HIST cohort [adjusted odds ratio (aOR) 1.31; 95% confidence interval (CI) 0.95–1.80]
and vs. the CONC cohort (aOR 1.89; 95% CI 1.37–2.61). In intention-to-treat (ITT) analysis (events:
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RAL, 50; HIST, 45; CONC, 127), the incidence of all new malignancies was 1.11 (95% CI 0.84–1.46)
per 100 PYFU in the RAL cohort vs. 1.20 (95% CI 0.90–1.61) and 0.83 (95% CI 0.70–0.99) in the
HIST and CONC cohorts, respectively. After adjustment, there was no evidence for a difference in
the risk of malignancies [adjusted rate ratio (RR) 0.73; 95% CI 0.47–1.14 for RAL vs. HIST; RR
0.95; 95% CI 0.65–1.39 for RAL vs. CONC] or mortality (adjusted RR 0.87; 95% CI 0.53–1.43 for
RAL vs. HIST; RR 1.14; 95% CI 0.76–1.72 for RAL vs. CONC).
Conclusions
We found no evidence for an oncogenic risk or poorer survival associated with using RAL
compared with control groups.
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Introduction
After the publication of the results of randomized clinical
trials performed against efavirenz-containing combina-
tion antiretroviral therapy (cART), raltegravir (RAL), the
first available antiretroviral agent belonging to the class
of HIV integrase strand transfer inhibitors (INSTIs), has
been approved for both ART-experienced patients and
first-line therapy in ART-na€ıve patients [1–6]. It was
widely introduced across Europe starting from 2010 [7].
Although a satisfactory tolerability profile in patients,
including those with underlying comorbidities, and
proportionally limited drug–drug interactions have gener-
ally been shown, a slight excess of cancers was observed
in interim analyses of clinical trials including RAL-based
regimens which was not, however, confirmed in subse-
quent analyses [8–13]. INSTIs bind at the active site of
HIV integrase and block the strand transfer step of inte-
gration. Recent in vitro studies showed that suboptimal
doses of RAL could lead to the generation of aberrant
proviruses during the strand transfer reaction, with sig-
nificant rearrangements of the host genome, including
duplications, inversions, deletions and, occasionally,
acquisition of sequences from other chromosomes
[14,15]. Based on what is known about the activation of
oncogenes in human tumours, it is possible that rear-
rangements in the host DNA (so far observed only in
in vitro models) as a result of potential aberrant HIV
DNA integrations could increase the chance that HIV
integrations could lead to the development of cancer.
In 2009, a large meta-analysis was conducted combin-
ing data from several randomized RAL clinical trials [16]
and found no difference in rates of cancer comparing
RAL users and people receiving other treatments. These
early results showed that, over the first 2 months of these
trials, cancer rates were similar in people who received
RAL and in controls. After 2 months in these studies,
cancers became more common in RAL users and the
number of new cancers then stabilized over time
(affecting about 1% of the patients enrolled over the fol-
lowing 20 months). Although there was no evidence for
statistical differences in rates of cancer between people
receiving RAL and those receiving standard of care, con-
cerns about the earlier findings led to further analyses
being conducted in observational studies to monitor
long-term safety profiles in RAL users.
The aim of this analysis was to compare the incidences
of malignancies and other comorbidities as well as
survival rates in cohorts of individuals initiating
RAL-based and non-RAL-based cART regimens in a large
European cohort of HIV-infected patients.
Methods
EuroSIDA is a large, on-going prospective cohort study
of 18 931 individuals living with HIV. The study collects
data from 111 hospitals in 34 different countries across
Europe, as well as Israel and Argentina [17,18]. Recruit-
ment started in 1994, and data are collected 6-monthly
on standardized case report forms (CRFs). Variables col-
lected include demographic information, CD4 counts,
viral load (VL) measurements and start and stop dates for
all antiretroviral drugs used. All patients gave informed
consent to be included in EuroSIDA at enrolment. Non-
AIDS-related events are collected in EuroSIDA following
the standardized HIV Cohorts Data Exchange Protocol
(HICDEP) code for data collection (http://www.hicdep.org/
wiki/Hicdep_1.90). Clinicians at EuroSIDA participating
sites were asked 6-monthly to report any event not previ-
ously reported to EuroSIDA, including all events since
the last follow-up. There is a specific “List of Definitions”
for the relevant events collected in EuroSIDA which fol-
lows the accepted World Health Organization Interna-
tional Classification of Diseases (WHO ICD). More detailed
information about the study can be found at www.c
phiv.dk.
Patients in EuroSIDA were included in the RAL cohort
if (1) they started RAL for the first time on or after 21
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December 2007 (the RAL authorization date in the Euro-
pean Union); (2) they had at least 1 month’s prospective
follow-up in this cohort, and (3) they had a CD4 count
and a VL measured within 6 months prior to the start date
of RAL. Two control cohorts were chosen a priori and
were defined as follows: a ‘historical’ (HIST) and a ‘con-
current’ (CONC) cohort. Patients were included in the HIST
comparison cohort if (1) they started a new antiretroviral
drug as part of a cART regimen on or after 1 January
2005 and before 21 December 2007 (patients must have
had no previous exposure to the new drug, including as
part of a different co-formulation, to be included); (2) they
had at least 1 month’s prospective follow-up in this
cohort, and (3) they had a CD4 count and a VL measured
within 6 months prior to the start date of the new drug.
Patients were included in the CONC cohort if (1) they
started a new antiretroviral drug other than RAL as part
of a cART regimen on or after 21 December 2007, and
had no previous exposure to the new drug, including as
part of a different co-formulation; (2) they had at least
1 month’s prospective follow-up in this cohort, and (3)
they had a CD4 count and a VL measured within
6 months prior to the start date of the new drug. Baseline
for the analysis in the RAL cohort was defined as the date
on which the patient first received RAL. In the HIST and
CONC cohorts, baseline was the date on which the patient
first received the new antiretroviral drug (not RAL).
Patients were allowed to contribute data to more than one
cohort, but with no overlap in the follow-up time (Fig. 1).
Those who contributed data to the HIST cohort were also
eligible for inclusion in the RAL cohort upon initiation of
RAL or in the CONC cohort upon initiation of a new
antiretroviral drug after 21 December 2007. Patients who
contributed data to the CONC cohort were also allowed to
‘switch’ into the RAL cohort upon initiation of RAL. How-
ever, in order to be able to evaluate the risk associated
with currently being exposed to RAL, patients in the RAL
cohort could not switch to the CONC cohort upon initia-
tion of a new antiretroviral drug.
Analyses were performed on the data set including
cumulated data collected from patient journals until
December 2014. The data were collected, keyed and qual-
ity assured at the Coordinating Centre between January
2014 and December 2014.
Statistical analysis
Four main outcomes were assessed: newly diagnosed
malignancies (AIDS- and non-AIDS-related), clinically
important hepatic events, lipodystrophy and mortality. By
protocol, a formal comparison of the incidence rates
between cohorts was performed only for outcomes with
> 30 events in all three comparator cohorts; this target
number of events was achieved only for the outcomes of
malignancies and overall mortality.
Patient’s follow-up time was defined as follows: only
prospectively collected person-years of follow-up (PYFU)
were included after the date of enrolment in EuroSIDA.
Follow-up time in the RAL cohort was censored at the
time of the earliest of any of the following events: dis-
continuation of RAL, death or last clinic visit. In the HIST
cohort, follow-up time was censored at the earliest of 21
December 2007, discontinuation of any new drugs started
on the baseline date, death or last clinic visit. In the
CONC cohort, follow-up time was censored at the earliest
of starting RAL (if started), discontinuation of any new
drugs started on the baseline date, death or last clinic
visit.
For the analysis of the incidence of clinical events, the
follow-up time included was additionally censored at the
first occurrence of the specific event of interest if it
occurred before the end of the follow-up period, but not
at the first occurrence of any of the other main outcomes.
As a consequence of the nature of how the data are
collected in our cohort, it is difficult to distinguish
between subsequent recurrences and continuations of
malignancies, and therefore only first occurrences of each
type were analysed in all incidence analyses. A further
analysis including all malignancies reported over the fol-
low-up time, regardless of whether or not they were first
occurrences, yielded similar results (not shown).
Baseline characteristics in the three cohorts were
compared using univariable and multivariable logistic
regression analysis. We also described the incidence of dis-
continuation of one or more drugs (main reason as reported
by the treating physician, for the RAL cohort alone).
The incidence of all outcomes was calculated as the
number of events over the follow-up period divided by
PYFU, assuming a Poisson distribution. Univariable and
multivariable Poisson regression models were used to esti-
mate rate ratios (RRs) of malignancies and of death
between the cohorts. Because of the large number of
potential measured confounders, propensity scores (PSs)
were used for the adjustment in the multivariable analysis.
All factors showing a univariable association with a = 0.1
were included in the PS vector. Quintiles of the PS were
fitted in the Poisson regression model as a continuous
variable. Results were consistent when we used the alter-
native approaches of matching, stratifying (data not
shown). For all Poisson regression analyses, an intention-
to-treat (ITT) approach, ignoring treatment switches as
well as recurrences of clinical events of the same type, was
used. All statistical analyses were performed using SAS
version 9.4 (SAS Institute, Cary, NC).
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Results
Study population
A total of 1470 patients were included in the RAL cohort,
3787 patients were included in the HIST comparison
cohort and 4467 patients were included in the CONC
cohort (Fig. 1). Table 1a shows a comparison of the
demographic characteristics of the patients in the three
cohorts at baseline. The majority of patients in all three
cohorts were male (approximately 75%) and of white eth-
nicity (> 84%). The mode of HIV transmission was similar
across the three cohorts. Approximately 40% of patients
were men who have sex with men (MSM), almost 20%
reported heterosexual contact as the mode of transmis-
sion, and approximately 30% were persons who inject
drugs (PWID). There was some difference in the
geographical distribution of the patients between the
cohorts; RAL users were mostly split between North Eur-
ope (21%), Central West Europe (36%) and South Europe
(31%), whereas approximately three-quarters of patients
in the HIST and CONC cohorts were evenly split between
North, Central West and South Europe, with the remain-
ing patients distributed between Central East and East
Europe, and just 1% in Argentina. The median age was
49 years in the RAL cohort, and 44 years in the HIST and
CONC cohorts. Baseline CD4 count was similar across the
three cohorts (medians between 392 and 468 cells/lL) but
CD4 count nadir was higher in the HIST and CONC
cohorts (medians 140 and 175 cells/lL, respectively, com-
pared with 118 cells/lL in the RAL cohort). There was a
shorter time from CD4 nadir to enrolment in both of the
comparison cohorts compared with the RAL cohort. On
average, RAL patients had been enrolled in EuroSIDA for
EuroSIDA patients
Total n = 18 914
Total 144 250 PYFU
Switched to RAL cohort
n = 302
623 PYFU
Switched to concurrent
cohort
n = 995
2328 PYFU
Historical cohort
n = 3787
4472 PYFU
Concurrent cohort
n = 4467
10 691 PYFU
RAL cohort
n = 1470
4058 PYFU
Switched to RAL cohort
n = 456
1403 PYFU
Included only in 
historical cohort
n = 2336
741 PYFU
Did not switch to RAL 
cohort
n = 4165
10 068 PYFU
Included in concurrent cohort
n = 3472
8363 PYFU
Included only in RAL cohort
n = 712
2032 PYFU
Not included in 
analysis
n = 10 943
129 383 PYFU
Fig. 1 Patients included in the analysis in the raltegravir (RAL), historical and concurrent cohorts. In order to obtain the total number of
patients in each cohort, it is sufficient to add the figures in the corresponding boxes, as follows. (1) The RAL cohort: 456 (historical patients
who switched to RAL over follow-up) + 302 (concurrent patients who switched to RAL) + 712 (patients originally included in the RAL
cohort) = 1470. (2) The historical cohort: 3787 (patients originally allocated to this group). The concurrent cohort: 3472 (patients originally
allocated to this group) + 995 (historical patients who switched to the concurrent cohort over follow-up) = 4467. PYFU, person-years of fol-
low-up.
© 2017 The Authors.
HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association
HIV Medicine (2018), 19, 102--117
Incidence of cancer and risk of mortality for RAL-based cART 105
longer than those in the comparison cohorts (median
11 months compared with 7 months in the HIST cohort
and 4 months in the CONC cohort). Median baseline VL
was 1.7 log10 HIV RNA copies/mL in the RAL cohort, 1.9
log10 copies/mL in the HIST cohort, and 1.8 log10 copies/
mL in the CONC cohort. Baseline VL was suppressed to
<= 500 copies/mL in 74% of the RAL cohort (60% were
suppressed to ≤ 50 copies/mL), 60% of the HIST cohort
(53% were suppressed to ≤ 50 copies/mL) and 58% of the
CONC cohort (56% were suppressed to ≤ 50 copies/mL),
and it was > 10 000 copies/mL in 14% of the RAL cohort,
27% of the HIST cohort and 33% of the CONC cohort.
Baseline peak VLs were also similar between the cohorts
(median 5.0 log10 copies/mL). Median baseline date for
the RAL cohort was February 2010, that for the HIST
cohort was September 2006 and that for the CONC cohort
was March 2009, and the median follow-up time was
35 months for the RAL cohort, 13 months for the HIST
cohort and 25 months for the CONC cohort. RAL patients
had a longer time since HIV-1-positive diagnosis (median
17 years compared with 12 years in the HIST cohort and
10 years in the CONC cohort). Only a minority of the
study population was ART-na€ıve at the date of inclusion
in this analysis (4% of the RAL cohort, 11% of the HIST
cohort and 30% of the CONC cohort). The prevalences of
hepatitis coinfection and comorbidities at baseline are
shown in Table 1b.
Predictors of RAL initiation
Table 2a shows the unadjusted and adjusted odds ratios
(aORs) for initiation of RAL vs. a historical agent. In the
unadjusted analysis, there were strong associations
between the probability of starting RAL and a large
number of the factors examined (P < 0.005). The multi-
variable model showed that, after adjustment for all sig-
nificant factors, older patients were more likely to receive
RAL [aOR per 10-year increase: 1.42; 95% confidence
interval (CI) 1.31–1.54], as were patients with a longer
time since CD4 count nadir (aOR per 1 year longer: 1.11;
95% CI 1.04–1.19), patients with a lower baseline VL
(aOR per 1 log10 copies/mL higher: 0.80; 95% CI 0.74–
0.85), patients with a higher peak VL at baseline (aOR per
1 log10 copies/mL higher: 1.26; 95% CI 1.17–1.36) and
patients who had been on ART for a longer period (aOR
per 1 year longer: 1.18; 95% CI 1.15–1.24). Patients visit-
ing a clinic in the North of Europe were less likely to
receive RAL compared with patients followed up in other
regions. Furthermore, higher numbers of previous nucle-
oside reverse transcriptase inhibitors (NRTIs) and protease
inhibitors (PIs) used were linked to increased odds of
starting RAL. For example, patients who had previously
received three or four PIs were more than twice as likely
to start RAL than those who had previously taken only
one or two PIs (aOR 1.79; 95% CI 1.50–2.14). Finally,
patients who had previously received treatment for an
opportunistic infection were less likely to receive RAL
(aOR 0.71; 95% CI 0.61–0.84), than patients who had pre-
viously experienced loss or accumulation of fat (aOR
0.45; 95% CI 0.39–0.52) (Table 2a). Results for the com-
parison between RAL recipients and the CONC cohort
were similar (Table 2b).
Drug discontinuation in the RAL cohort
A total of 351 patients (24%) discontinued RAL, of whom
39 (11%) discontinued within 3 months. Of the 351
discontinuations, 140 (40%) involved the discontinuation
of RAL alone, while in the remaining 211 instances at
least one additional drug was discontinued together with
RAL (60%). The other drugs most frequently leading to
the 351 discontinuations of the RAL regimen were riton-
avir (18%), emtricitabine/tenofovir (16%), lamivudine
(8%) maraviroc and tenofovir (7%), and atazanavir and
efavirenz (6%). Of the 39 discontinuations that occurred
within 3 months, 16 (41%) were of RAL alone.
Focussing on these 39 early discontinuations (within
3 months), they were mainly attributable to gastrointesti-
nal toxicity (n = 4) and patient choice (n = 10), whereas
the majority of the 312 longer term discontinuations
(after the first 3 months) seemed to be attributable to
physician decision (including structured treatment inter-
ruptions) (n = 71), patient wish (n = 63) or clinicians
reporting treatment failure (n = 28), while only 10 were
attributable to gastrointestinal toxicity.
Clinical outcomes
A total of 222 malignancies occurred over the follow-
up time, after excluding 13 recurrent events (five in
the RAL cohort, two in the HIST cohort and six in the
CONC cohort). This included 50 malignancies over the
follow-up time in the RAL cohort, 45 in the HIST
cohort and 127 in the CONC cohort. AIDS-defining
malignancies, including Kaposi’s sarcoma and non-
Hodgkin’s lymphoma, were reported in 14% of diag-
noses in the RAL cohort (one case of Kaposi’s sarcoma
and six cases of non-Hodgkin’s lymphoma), 29% of
diagnoses in the HIST cohort (five cases of Kaposi’s
sarcoma and eight cases of non-Hodgkin’s lymphoma)
and 16% of diagnoses in the CONC cohort (10 cases of
Kaposi’s sarcoma and 10 cases of non-Hodgkin’s
lymphoma). The breakdown of all specific cancer loca-
tions, including the remaining non-AIDS-related events,
© 2017 The Authors.
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Table 1 Baseline* patient characteristics. (a) Baseline comorbidities and prior clinical events according to inclusion in the raltegravir (RAL),
historical and concurrent cohorts. (b) Baseline information on hepatitis coinfection status, comorbidities and prior clinical events according to
inclusion in the RAL, historical and concurrent cohorts
RAL Historical Concurrent
(a)
Total number 1470 3787 4467
Gender [n (%)]
Female 361 (24.6) 949 (25.1) 1229 (27.5)
Mode of HIV transmission [n (%)]
MSM 640 (43.5) 1623 (42.9) 1782 (39.9)
Heterosexual contacts 255 (17.3) 764 (20.2) 860 (19.3)
PWID 451 (30.7) 1129 (29.8) 1539 (34.5)
Other/unknown 124 (8.4) 271 (7.2) 286 (6.4)
Ethnicity [n (%)]
White 1232 (83.8) 3274 (86.5) 3942 (88.2)
Asian 20 (1.4) 62 (1.6) 56 (1.3)
Black 90 (6.1) 239 (6.3) 282 (6.3)
Other/unknown 128 (8.7) 212 (5.6) 187 (4.2)
Country of origin [n (%)]
Same country as clinic 1142 (77.7) 2902 (76.6) 3539 (79.2)
Other European country 82 (5.6) 212 (5.6) 225 (5.0)
Africa 94 (6.4) 243 (6.4) 284 (6.4)
America 32 (2.2) 133 (3.5) 168 (3.8)
Asia 17 (1.2) 48 (1.3) 53 (1.2)
Other/unknown 103 (7.0) 249 (6.6) 198 (4.4)
Geographical region [n (%)]
South 458 (31.2) 1131 (29.9) 1053 (23.6)
Central West 523 (35.6) 892 (23.6) 889 (19.9)
North 315 (21.4) 1071 (28.3) 891 (19.9)
Central East 138 (9.4) 394 (10.4) 777 (17.4)
East 21 (1.4) 190 (5.0) 696 (15.6)
Argentina 15 (1.0) 109 (2.9) 161 (3.6)
Viral load [n (%)]
< 500 copies/mL 1082 (73.6) 2278 (60.2) 2584 (57.8)
500–10 000 copies/mL 179 (12.2) 486 (12.8) 411 (9.2)
> 10 000 copies/mL 209 (14.2) 1023 (27.0) 1472 (33.0)
Age (years) [median (IQR)] 49 (44, 56) 44 (39, 50) 44 (35, 51)
CD4 count
Baseline (cells/lL) [median (IQR)] 468 (300, 673) 392 (237, 614) 404 (255, 630)
Nadir (cells/lL) [median (IQR)] 118 (41, 208) 140 (50, 225) 175 (75, 266)
Time since nadir (years) [median (IQR)] 10 (4, 13) 6 (2, 9) 4 (0, 10)
Viral load (log10 copies/mL) [median (IQR)]
Baseline 1.7 (1.6, 2.9) 1.9 (1.7, 4.2) 1.8 (1.6, 4.5)
Peak 5.0 (4.3, 5.6) 4.9 (4.2, 5.5) 5.0 (4.3, 5.5)
Index date (baseline) [median (IQR)] 2010 (2009, 2012) 2006 (2005, 2006) 2009 (2008, 2011)
Length of follow-up (months) [median (IQR)] 32 (15, 52) 13 (6, 22) 25 (11, 45)
Time HIV-1 positive (years) [median (IQR)]† 17 (13, 21) 12 (8, 16) 10 (4, 16)
History of ART [n (%)]
ART-na€ıve 58 (3.9) 424 (11.2) 1339 (30.0)
(b)
Total number 1470 3787 4467
HBV coinfection status [n (%)]‡
Positive 92 (6.3) 287 (7.6) 279 (6.2)
Negative 1278 (86.9) 3160 (83.4) 3672 (82.2)
Unknown 100 (6.8) 340 (9.0) 516 (11.6)
HCV coinfection status [n (%)]§
Positive 376 (25.6) 954 (25.2) 1109 (24.8)
Negative 962 (65.4) 2213 (58.4) 2622 (58.7)
Unknown 132 (9.0) 620 (16.4) 736 (16.5)
Prior clinical events¶
No. of previous AIDS diagnoses [n (%)]
0 921 (62.7) 2577 (68.0) 3350 (75.0)
1 311 (21.2) 760 (20.1) 764 (17.1)
2 144 (9.8) 270 (7.1) 240 (5.4)
≥ 3 94 (6.4) 180 (4.8) 113 (2.5)
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stratified by cohort, is shown in Supporting Information
Table S1.
The incidence of newly diagnosed malignancies (222
events over 23 501 PYFU) was 0.94 (95% CI 0.82–1.08)
per 100 PYFU; the incidence of death (197 events/23 936
PYFU) was 0.82 (95% CI 0.71–0.95), that of lipodystrophy
(189/23 510 PYFU) was 0.80 (95% CI 0.69–93) and that
of hepatic events (82/23 713 PYFU) was 0.35 (95% CI
0.28–0.43). After stratification by cohort, the rates of
cancer were 1.1 (95% CI 0.8–1.5), 1.2 (95% CI 0.9–1.6)
and 0.8 (95% CI 0.7–1.0) per 100 PYFU in the RAL, HIST
and CONC cohorts, respectively. The corresponding
mortality rates by cohort remained low at 1.0 (95% CI
0.7–1.3), 0.9 (95% CI 0.6–1.3) and 0.8 (95% CI 0.6–0.9)
per 100 PYFU (Table 3).
For reasons described in the Methods, adjusted RRs
from fitting a Poisson regression are shown only for the
endpoints of malignancies and death. The unadjusted
analysis for cancer showed a 40% increase in the risk of
malignancies for people who started RAL compared with
people in the CONC cohort (Table 4a). However, after
controlling for a number of potential confounders identi-
fied in Table 2, using standard regression adjustment, the
estimated RR was closer to the null and not significant
(comparing RAL with CONC: unadjusted RR 1.33; 95% CI
0.96–1.85; P = 0.08; adjusted RR 0.98; 95% CI 0.67–1.41;
P = 0.90; Table 4a). The adjusted estimate obtained from
fitting the quintiles of the PSs as a continuous covariate
in the model was consistent with this estimate (RR 0.95;
95% CI 0.65–1.39; P = 0.79). Figure S1a and b in the
Supporting Information show the overlap in the PS distri-
butions in the three cohorts which allowed a meaningful
observational comparison using this strategy to control
for confounding.
In order to test the hypothesis that the difference in
the risk of malignancies between people receiving RAL
and control cohorts might vary according to previous
history of ART, we stratified the PS analysis to separate
people who had previously experienced virological failure
to a maximum of two drugs and those who had experi-
enced failure to more than two drugs, and we found no
evidence for such an interaction (P = 0.77). Similarly, we
found no evidence for an interaction with baseline VL
(when using a binary variable with a cut-off of 400
copies/mL; P = 0.92).
Again, there was no difference in the incidence of
death between the RAL and HIST cohorts. In the unad-
justed analysis, there was a trend for a greater risk of
mortality in the CONC cohort compared with the RAL
cohort (RR 1.35; 95% CI 0.96–1.89; P = 0.08). However,
this difference was attenuated and not significant after
controlling for potential confounders (RR 1.14; 95% CI
Table 1 (Continued )
RAL Historical Concurrent
AIDS-defining conditions, excluding malignancies [n (%)] 495 (33.7) 1086 (28.7) 1009 (22.6)
AIDS dementia complex [n (%)] 30 (2.0) 52 (1.4) 36 (0.8)
Candidiasis [n (%)] 164 (11.2) 332 (8.8) 302 (6.8)
CMV infection [n (%)] 32 (2.2) 62 (1.6) 42 (0.9)
HIV wasting syndrome [n (%)] 43 (2.9) 95 (2.5) 100 (2.2)
Mycobacterium tuberculosis infection [n (%)] 84 (5.7) 245 (6.5) 221 (4.9)
PCP [n (%)] 149 (10.1) 342 (9.0) 266 (6.0)
Toxoplasmosis [n (%)] 45 (3.1) 93 (2.5) 82 (1.8)
AIDS-related malignancy [n (%)] 123 (8.4) 238 (6.3) 191 (4.3)
Non-AIDS-related malignancy [n (%)] 99 (6.7) 108 (2.9) 101 (2.3)
Cardiovascular event [n (%)] 92 (6.3) 109 (2.9) 108 (2.4)
Pancreatitis/end-stage renal disease [n (%)] 26 (1.8) 31 (0.8) 28 (0.6)
Hepatic encephalopathy [n (%)] 41 (2.8) 74 (2.0) 65 (1.5)
Loss or accumulation of fat [n (%)] 820 (55.8) 1802 (47.6) 1350 (30.2)
Ever discontinued a drug because of liver toxicity [n (%)] 99 (6.7) 162 (4.3) 160 (3.6)
Ever discontinued a drug because of lipodystrophy/atrophy [n (%)] 360 (24.5) 816 (21.5) 687 (15.4)
Time since first AIDS diagnosis (years) [median (IQR)]# 12 (8, 14) 9 (5, 10) 8 (3, 13)
Time since last AIDS diagnosis (years) [median (IQR)]# 11 (7, 14) 8 (4, 10) 8 (3, 12)
CMV, cytomegalovirus; HBV, hepatitis B virus; HCV, hepatitis C virus; IDU, injecting drug use; IQR, interquartile range; PCP, Pneumocystis carinii pneu-
monia; TB, tuberculosis.
*Baseline date in the RAL cohort is defined as the date on which the patient first received RAL, and in the historical and concurrent cohorts, it was
the date on which the patient first received the new antiretroviral drug (not RAL).
†
Missing data for 26 (3.1%) patients in the RAL cohort, 53 (2.0%) patients in the historical cohort and 157 (5.3%) patients in the concurrent cohort.
‡
Hepatitis B virus surface antigen (HBsAg) test results.
§
Hepatitis C virus antibody (HCVAb) test results.
¶
Prior clinical events refer to any events that occurred before baseline. AIDS-defining diseases are listed for those that occurred in more than 30
patients.
#
In those with a previous AIDS (malignancy or nonmalignancy) diagnosis.
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Table 2 Unadjusted and adjusted odds ratios (ORs) for initiation of raltegravir (RAL) compared with (a) the historical cohort and (b) the
concurrent cohort
Factor
Unadjusted Adjusted
OR (95% CI) P-value OR (95% CI) P-value
(a)
Gender
Male 1.00
Female 0.97 (0.86, 1.10) 0.672
Mode of HIV transmission
MSM 1.00 0.329
IDU 0.85 (0.73, 0.98)
Heterosexual 1.01 (0.89, 1.15)
Other 1.16 (0.95, 1.42)
Ethnicity
White 1.00
Other/unknown 1.23 (1.07, 1.43) 0.005 1.15 (0.94, 1.40) 0.168
Geographical region
North 1.00 < 0.001 1.00 < 0.001
Central West 1.99 (1.72, 2.31) 1.68 (1.39, 2.02)
South/Argentina 1.30 (1.12, 1.50) 1.73 (1.42, 2.11)
Central East/East 0.93 (0.76, 1.13) 2.92 (2.21, 3.87)
HBV coinfection
Negative 1.00 0.417
Positive 0.79 (0.64, 0.99)
Unknown 0.73 (0.58, 0.90)
HCV coinfection
Negative 1.00 < 0.001 0.498
Positive 0.91 (0.80, 1.03) 0.78 (0.66, 0.91)
Unknown 0.49 (0.40, 0.59) 0.62 (0.49, 0.78)
Age (per 10 years older) 1.74 (1.64, 1.84) < 0.001 1.40 (1.29, 1.52) < 0.001
CD4 count (per 100 cells/lL higher)
Baseline 1.08 (1.06, 1.10) < 0.001
Nadir 0.91 (0.87, 0.96) < 0.001 1.11 (1.04, 1.19) 0.002
Time since CD4 count nadir (per 1 year longer) 1.17 (1.16, 1.19) < 0.001 1.05 (1.03, 1.07) < 0.001
Viral load (per log10 copies/mL higher)
Baseline 0.75 (0.71, 0.79) < 0.001 0.80 (0.74, 0.85) < 0.001
Peak 1.05 (1.00, 1.11) 0.069 1.26 (1.17, 1.36) < 0.001
Length of enrolment in EuroSIDA (per 1 year longer) 1.17 (1.15, 1.19) < 0.001 1.05 (1.03, 1.07) < 0.001
Prior clinical events (vs. no event)
No. of previous AIDS diagnoses
0 1.00 1.00
1 1.14 (1.00, 1.31) 0.052 0.99 (0.83, 1.18) 0.914
≥ 2 1.48 (1.27, 1.72) < 0.001 1.27 (1.02, 1.58) 0.033
AIDS-related malignancy 1.36 (1.12, 1.65) 0.002 0.87 (0.67, 1.12) 0.279
Non-AIDS-related malignancy 2.46 (1.90, 3.18) < 0.001 1.31 (0.95, 1.80) 0.099
Cardiovascular event 2.25 (1.74, 2.92) < 0.001 1.19 (0.87, 1.64) 0.280
Loss or accumulation of fat 1.39 (1.25, 1.55) < 0.001 0.45 (0.39, 0.52) < 0.001
Discontinued drug because of toxicity 1.62 (1.28, 2.04) < 0.001 1.15 (0.86, 1.54) 0.340
Discontinued drug because of lipodistrophy/atrophy 1.18 (1.04, 1.34) 0.010 0.90 (0.77, 1.05) 0.165
Prior medication (vs. no medication)
OI treatment* 1.40 (1.25, 1.57) < 0.001 0.71 (0.61, 0.84) < 0.001
Lipid-lowering agents 1.56 (1.30, 1.88) < 0.001 0.82 (0.67, 1.02) 0.070
Prior ART
Time since started ART (per 1 year longer) 1.24 (1.21, 1.26) < 0.001 1.18 (1.15, 1.21) < 0.001
No. of previous treatment failures (per one higher) 1.47 (1.40, 1.54) < 0.001 0.72 (0.66, 0.80) < 0.001
No. of previous NRTIs
3–4 1.00 1.00
0–2 0.66 (0.55, 0.79) < 0.001 1.79 (1.42, 2.27) < 0.001
≥ 5 3.19 (2.77, 3.67) < 0.001 1.89 (1.59, 2.26) < 0.001
No. of previous NNRTIs
1 1.00 1.00
0 0.32 (0.28, 0.37) < 0.001 0.51 (0.34, 0.77) 0.001
≥ 2 1.39 (1.20, 1.60) < 0.001 0.95 (0.80, 1.13) 0.587
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Table 2 (Continued )
Factor
Unadjusted Adjusted
OR (95% CI) P-value OR (95% CI) P-value
No. of previous PIs
1–2 1.00 1.00
0 0.55 (0.46, 0.67) < 0.001 1.42 (1.02, 1.98) 0.038
3–4 2.66 (2.30, 3.07) < 0.001 1.79 (1.50, 2.14) < 0.001
≥ 5 4.45 (3.72, 5.32) < 0.001 3.20 (2.47, 4.15) < 0.001
Ever previously exposed to ART 3.38 (3.00, 3.81) < 0.001 1.10 (0.71, 1.70) 0.681
(b)
Gender
Male 1.00
Female 0.86 (0.75, 0.98) 0.021
Mode of HIV transmission
MSM 1.00 0.254
IDU 0.83 (0.70, 0.97)
Heterosexual 0.82 (0.72, 0.93)
Other 1.21 (0.97, 1.50)
Ethnicity
White 1.00 1.00
Other/unknown 1.45 (1.24, 1.69) < 0.001 1.15 (0.91, 1.46) 0.240
Geographical region
North 1.00 < 0.001 1.00 < 0.001
Central West 1.66 (1.42, 1.95) 1.55 (1.29, 1.85)
South/Argentina 1.10 (0.94, 1.29) 1.31 (1.09, 1.59)
Central East/East 0.31 (0.25, 0.37) 0.76 (0.60, 0.96)
HBV coinfection
Negative 1.00 < 0.001 0.002
Positive 0.95 (0.76, 1.19) 0.63 (0.48, 0.82)
Unknown 0.56 (0.45, 0.69) 0.94 (0.72, 1.23)
HCV coinfection
Negative 1.00 < 0.001
Positive 0.92 (0.81, 1.05)
Unknown 0.49 (0.40, 0.59)
Age (per 10 years older) 1.65 (1.57, 1.74) < 0.001 1.22 (1.13, 1.31) < 0.001
CD4 count (per 100 cells/lL higher)
Baseline 1.05 (1.03, 1.06) < 0.001
Nadir 0.76 (0.72, 0.80) < 0.001 0.99 (0.93, 1.05) 0.715
Time since CD4 count nadir (per 1 year longer) 1.12 (1.11, 1.14) < 0.001 1.01 (0.99, 1.02) 0.419
Viral load (per log10 copies/mL higher)
Baseline 0.74 (0.71, 0.77) < 0.001 1.00 (0.93, 1.07) 0.975
Peak 1.03 (0.97, 1.08) 0.349 0.96 (0.90, 1.03) 0.270
Length of enrolment in EuroSIDA (per 1 year longer) 1.13 (1.12, 1.14) < 0.001 1.00 (0.98, 1.02) 0.830
Prior clinical events (vs. no event)
No. of previous AIDS diagnoses
0 1.00 1.00
1 1.48 (1.28, 1.71) < 0.001 0.97 (0.81, 1.15) 0.708
≥ 2 2.45 (2.07, 2.90) < 0.001 1.27 (1.01, 1.60) 0.037
AIDS-related malignancy 2.04 (1.64, 2.54) < 0.001 0.92 (0.70, 1.21) 0.559
Non-AIDS-related malignancy 3.12 (2.39, 4.08) < 0.001 1.89 (1.37, 2.61) < 0.001
Cardiovascular event 2.69 (2.06, 3.53) < 0.001 1.35 (0.99, 1.83) 0.055
Loss or accumulation of fat 2.91 (2.60, 3.27) < 0.001 0.95 (0.81, 1.11) 0.516
Discontinued drug because of toxicity 1.94 (1.53, 2.46) < 0.001 1.09 (0.83, 1.42) 0.550
Discontinued drug because of lipodistrophy/atrophy 1.78 (1.56, 2.04) < 0.001 1.04 (0.88, 1.23) 0.642
Prior medication (vs. no medication)
OI treatment* 2.51 (2.23, 2.82) < 0.001 0.88 (0.75, 1.03) 0.109
Lipid-lowering agents 1.88 (1.54, 2.28) < 0.001 0.75 (0.60, 0.94) 0.012
Prior ART
Time since started ART (per 1 year longer) 1.16 (1.15, 1.17) < 0.001 0.99 (0.96, 1.01) 0.281
No. of previous treatment failures (per one higher) 2.33 (2.20, 2.47) < 0.001 1.29 (1.17, 1.42) < 0.001
No. of previous NRTIs
3–4 1.00 1.00
0–2 0.31 (0.26, 0.37) < 0.001 0.89 (0.70, 1.12) 0.313
≥ 5 3.35 (2.89, 3.88) < 0.001 1.70 (1.43, 2.03) < 0.001
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Table 3 Overall incidence of outcomes: unadjusted analysis
RAL Historical Concurrent
No. of events PYFU
Incidence per 100
PYFU (95% CI) No. of events PYFU
Incidence per
100 PYFU (95% CI)
No. of
events PYFU
Incidence per 100
PYFU (95% CI)
Malignancies 50 4505.0 1.11 (0.84, 1.46) 45 3748.5 1.20 (0.90, 1.61) 127 15 247 0.83 (0.70, 0.99)
Clinically important
hepatic events
3 4583.0 0.07 (0.02, 0.20) 41 3750.8 1.09 (0.80, 1.48) 38 15 379 0.25 (0.18, 0.34)
Lipodystrophy 14 4559.9 0.31 (0.18, 0.52) 77 3712.0 2.07 (1.66, 2.59) 98 15 238 0.64 (0.53, 0.78)
Mortality 47 4656.2 1.01 (0.76, 1.34) 34 3780.2 0.90 (0.64, 1.26) 116 15 500 0.75 (0.62, 0.90)
CI, confidence interval; PYFU, person-years of follow-up; RAL, raltegravir.
Table 4 Unadjusted and adjusted relative risks (RRs) of (a) malignancies and (b) death from fitting a Poisson regression analysis using
standard adjustment and propensity scores
Unadjusted Standard regression adjustment
Propensity score* quintile
regression adjustment
RR (95% CI) P-value RR (95% CI) P-value RR (95% CI) P-value
(a)
Historical control comparison
Historical control 1.00 1.00 1.00
Raltegravir 0.92 (0.62, 1.38) 0.703 0.73 (0.47, 1.14) 0.169 0.81 (0.53, 1.26) 0.350
Concurrent control comparison
Concurrent control 1.00 1.00 1.00
Raltegravir 1.33 (0.96, 1.85) 0.086 0.95 (0.65, 1.39) 0.787 0.98 (0.67, 1.41) 0.897
(b)
Historical control comparison
Historical control 1.00 1.00 1.00
Raltegravir 1.12 (0.72, 1.74) 0.608 0.87 (0.53, 1.43) 0.593 0.90 (0.56, 1.45) 0.660
Concurrent control comparison
Concurrent control 1.00 1.00 1.00
Raltegravir 1.35 (0.96, 1.89) 0.084 1.14 (0.76, 1.72) 0.523 1.22 (0.83, 1.80) 0.320
*Factors included in the vector to construct propensity scores in the two comparisons were: gender, ethnicity, country of origin, geographical region,
hepatitis B virus coinfection, hepatitis C virus coinfection, age, CD4 count, time since CD4 count nadir, baseline viral load, length of enrolment in
EuroSIDA, comorbidities, loss or accumulation of fat, opportunistic infection treatment use, time since starting antiretroviral therapy, number of previ-
ous treatment failures, number of previous nucleoside reverse transcriptase inhibitors, number of previous nonnucleoside reverse transcriptase inhibi-
tors, number of previous protease inhibitors and number of previous drug classes used.
Table 2 (Continued )
Factor
Unadjusted Adjusted
OR (95% CI) P-value OR (95% CI) P-value
No. of previous NNRTIs
1 1.00 1.00
0 0.26 (0.23, 0.30) < 0.001 0.35 (0.25, 0.49) < 0.001
≥ 2 2.39 (2.02, 2.83) < 0.001 1.38 (1.14, 1.68) < 0.001
No. of previous PIs
1–2 1.00 1.00
0 0.22 (0.18, 0.26) < 0.001 0.34 (0.24, 0.47) < 0.001
3–4 2.53 (2.19, 2.94) < 0.001 1.52 (1.28, 1.80) < 0.001
≥ 5 7.04 (5.60, 8.86) < 0.001 2.82 (2.12, 3.74) < 0.001
Previously taken NRTIs, NNRTIs or PIs 5.55 (4.91, 6.27) < 0.001 0.54 (0.37, 0.78) 0.001
ART, antiretroviral therapy; CI, confidence interval; IDU, injecting drug use; MSM, men who have sex with men; NRTI, nucleoside reverse transcriptase
inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
Multivariable analysis was adjusted for all variables where multivariable ORs are shown. P-values were obtained using logistic regression.
*Prior opportunistic infection (OI) treatment includes treatment for Pneumocystis carinii pneumonia/toxoplasmosis and (brain) Mycobacterium tubercu-
losis, fungal, hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus and herpes simplex virus infections, and immunomodulating therapy.
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0.76–1.72; P = 0.52; Table 4b). After controlling for the
confounding factors included in the PS vector, the
adjusted RRs were also closer to the value of 1.0 for
the comparisons with both the HIST (RR 0.90; 95% CI
0.56–1.45; P = 0.66) and CONC (RR 1.22; 95% CI 0.83–
1.80; P = 0.32) cohorts. In the analysis of the unad-
justed RRs stratified by PS quintiles, again the results
were similar (data not shown). After restricting the
analysis to people who developed Hodgkin’s or non-
Hodgkin’s lymphomas (n = 37 events), the unadjusted
RRs were 0.68 (95% CI 0.28–1.64; P = 0.39) when
comparing the RAL cohort with the HIST cohort and
2.03 (95% CI 0.89–4.64; P = 0.093) when comparing
the RAL cohort with the CONC cohort. The latter was
attenuated to a RR of 1.73 (95% CI 0.66–4.57;
P = 0.26) after controlling for PSs (quintile adjustment).
Discussion
Soon after the advent of cART, observational studies
detected a major reduction in the incidence of Kaposi’s
sarcoma and non-Hodgkin’s lymphoma following cART
initiation among treatment-na€ıve HIV-infected persons
[16,17,19]. The benefit of cART in reducing cancer risk
could be explained by suppression of HIV replication,
immune function improvement or reduction of inflamma-
tion. Some studies also showed a decreased incidence of
malignancies not driven by infection with increased cART
exposure [20–24]. Therefore, global improvement of
immune surveillance against cancer cells was also postu-
lated as a likely mediator of the benefit of cART in
reducing cancer risk [25]. However, experimental data
suggest that specific drugs, such as RAL, may have
potential carcinogenic effects [14,15,26,27].
Our analysis, conducted in a large observational cohort
of HIV-infected people receiving RAL, showed no evi-
dence that using RAL was associated with an increased
risk of cancer or death compared with other concomitant
treatment strategies or a historical control group of indi-
viduals on ART. This is largely consistent with a recent
meta-analysis of two large randomized clinical trials of
people using RAL (the STARTMRK and BENCHMRK trials)
which reported a low risk of adverse events in RAL recip-
ients and no difference in the RR of cancer comparing
RAL with efavirenz (RR 0.75; 95% CI 0.30, 1.91) [28,29].
Our analysis extends these results to a longer follow-up
than that observed in these trials.
In a previous meta-analysis of clinical trials comparing
RAL with other agents, 46 participants developed 53
cases of cancer over the follow-up period [28]. Com-
monly detected cancers included Kaposi’s sarcoma, anal
or rectal cancer, cancer of the immune system and
lymphomas. These were also cancers frequently reported
in our analysis, but there was no particular diagnosis that
appeared more frequently than expected on the basis of
findings in similar HIV-infected populations. If anything,
there was a trend favouring RAL for the incidence of
Kaposi’s sarcoma (2% in RAL recipients) compared with
the HIST (11%) and CONC (8%) cohorts, which should
perhaps be investigated in larger studies. Similarly, the
incidence of serious hepatic events was found in our
analysis to be substantially lower in people using RAL
(Table 3). Unfortunately, the small number of events did
not allow us to further investigate in a multivariable
analysis whether this held true after controlling for
baseline imbalances in other factors.
In the trials, cancers were more common in ART-
experienced patients, possibly because of the patients’
weaker immunity, indicated by a generally lower CD4
count at enrolment [28,29]. Cancer typically tends to take
years to develop but it is possible that tumours grow fas-
ter in people with advanced HIV disease, despite immune
restoration, as a consequence of ongoing inflammation
and increased coagulation associated with the use of ART
[30,31].
EuroSIDA represents an ideal setting in which to evalu-
ate long-term outcomes in a heterogeneous population
with moderate to extensive pretreatment history and
offered the possibility to identify suitable ‘control’ groups
of patients who initiated RAL-sparing treatment regimens.
Indeed, well-known limitations of randomized clinical tri-
als are the selection of patients included (e.g. female
patients and populations with lifestyle factors associated
with nonadherence and mortality are under-represented
in trials) and lack of data on the long-term risk of clinical
events. Although our follow-up was a little shorter than
3 years, this is longer than the follow-up period of any
trial previously conducted in people receiving RAL-based
regimens. Thus, with the caveat that other types of bias
may be present (mainly because of a lack of randomiza-
tion), analyses of observational data can provide insights
into the risk of these long-term outcomes. A recent
French study (the Racing cohort) in 482 RAL-treated
patients exposed to RAL for >12 months and with avail-
able data, in a real-life setting like ours, reported an ele-
vated rate and variety of comorbidities and a variable
adherence rate, but confirmed excellent efficacy and tol-
erability results, which were comparable to those
observed in randomized registration trials [28,29]. In par-
ticular, of the 134 reported and treatment-related adverse
events (AEs), the symptoms most frequently described
(> 5%) were myalgia (7%) and nausea (5%). A total of 34
serious AEs were reported, of which five were possibly or
probably related to RAL. In general, a favourable
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tolerability profile has been demonstrated for RAL since
the earlier registration studies, with headache and gas-
trointestinal complaints representing the most common
reported AEs [28,32–35]. In contrast, mild neuropsychi-
atric disorders have been infrequently recorded (usually
reported on a subjective basis), and cases of rhabdomy-
olisis and hypersensitivity reactions have been extremely
rare. Finally, there is little evidence that the serum lipid
profile is modified by RAL, especially when compared
with regimens containing older PIs and also efavirenz. On
this basis, it has been suggested by Lee and Carr that
RAL should be a preferred option for patients with a pre-
existing risk of cardiovascular diseases, altered serum
lipid levels, metabolic syndrome, or changes in body fat
composition (i.e. the lipodystrophy syndrome) [36]. Man-
fredi R et al., in an analysis of a large hospital database
in Italy, showed that grade 2–4 AEs attributable to RAL
were neither directly observed nor reported in the self-
completed record of possible untoward events filled in
every month by patients at the time of repeat prescrip-
tion, and double-checked by hospital pharmacists and
physicians. In contrast, the discontinuation of some com-
panion drugs at the time of RAL introduction and during
the 12-month follow-up [especially NRTIs, some selected
PIs and nonnucleoside reverse transcriptase inhibitors
(NNRTIs), and enfuvirtide] had a favourable effect on the
tolerability of the RAL-based regimens [37]. In addition,
no clinical or laboratory evidence of autoimmune disor-
ders associated with exposure to RAL-containing cART
regimens was found, as also reported in a recent 12-
month observational study [38].
In our analysis, discontinuation was examined in the
RAL cohort alone, and we found a risk of discontinuation
similar to those reported in the trials. The main reason
for stopping RAL appeared to be physician’s choice.
Although the exact reason reported by the physician
under ‘physician’s choice’ is not specified in the Euro-
SIDA data collection report forms, it is conceivable that
discontinuations because of toxicity induced by RAL
would be filed under the reason ‘toxicity’, not ‘physician’s
choice’. There was also a nonnegligible frequency of peo-
ple with missing information regarding the reason for
stopping, which reflects the way the date are collected, as
reasons are often not known or reported in clinical
patient notes. We cannot rule out that some of these
might be due to toxicity.
We also found that, at the time of treatment initiation,
individuals in the RAL cohort tended to be different from
those in the HIST and CONC control groups: RAL recipi-
ents were typically older with a longer time since CD4
count nadir, a lower baseline VL and a longer duration of
ART. There were also differences by geographical region,
previous drug history (RAL recipients had been treated
more extensively in the past) and past comorbidities (pa-
tients in the RAL cohort were less well). However, once
these differences had been taken into account using stan-
dard and more sophisticated statistical modelling, we
found no difference in the risk of the two main clinical
outcomes analysed (risk of malignancy and death) com-
pared with those starting other historical or concurrent
cART regimens. Results were similar in people with little
and those with more extensive pretreatment drug history,
although the power to study such an interaction was low.
Further studies with larger numbers of malignancies need
to be conducted in order to determine whether the risk of
cancer might vary according to the extent of previous
virological failure or the extent of exposure to RAL (in
vitro risk was highest in those with suboptimal expo-
sure)..
Before drawing firm conclusions, it should be noted
that ours are observational cohort study data and hence
need to be interpreted practically, realistically and with
full knowledge of their limitations and inherent potential
biases. While there are extensive data quality pro-
grammes in place within EuroSIDA, it remains an obser-
vation of routine clinical practice across Europe. As a
consequence, although it was reassuring to see that our
analyses using a range of techniques aimed at reducing
bias caused by confounding, led to similar results, we are
not able to exclude the possibility of confounding by
indication or other bias introduced by unmeasured
confounders (such as traditional lifestyle risk factors for
cancer such as smoking) that can only be truly accounted
for in a randomized clinical trial. In the specific case of
patients who are about to receive chemotherapy, patients
are typically switched to RAL to minimize pharmacoki-
netic interactions. Some of the residual excess risk of
death seen in the RAL vs. CONC analysis might be
explained by this important unmeasured source of
confounding.
Although the list of clinical diagnoses collected in the
database follows the accepted classification of the WHO
ICD, a central pathological review was not conducted.
Specifically, as data are collected in infectious diseases
and internal medicine departments, there is a risk of
under-reporting of non-AIDS-defining cancers, when
there is no linkage with cancer registries. There is also a
risk of misclassification, in particular for cancers such as
anal cancer, which was particularly frequent in all three
cohorts. Furthermore, for the primary endpoint of malig-
nancies, because of the relatively small number of events
observed, a certain degree of uncertainty around our esti-
mates remains, calling for additional confirmatory analy-
ses in larger data sets. In our analysis, loss to follow-up
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and death from causes other than cancer may act as com-
peting risks which have not be accounted for. The small
overall number of cancers did not allow a fully adjusted
comparison after restriction to specific diagnoses. How-
ever, because direct HIV-1-related integrase inhibitor-
induced genome alterations are expected to affect only
HIV-1-permissive cells, especially CD4 T cells, macro-
phages and glia cells [14,15], we restricted the analysis to
37 events of Hodgkin’s or non-Hodgkin’s lymphomas,
and the unadjusted RRs were similar. Overall, there was
no evidence that results varied by level of HIV replica-
tion. Neither host DNA or INSTI resistance data were
available to evaluate the prevalence of RAL-induced
mutations potentially associated with an increased risk of
cancer.
In conclusion, our findings show that use of RAL
does not seem to be associated with an increased risk
of cancer or reduced survival when compared with the
cancer and survival rates seen in people treated with
alternative regimens in routine clinical care. With all
the caveats of a comparison conducted in observational
settings, our data, confirm that RAL is a safe and valid
therapeutic option, especially for patients with a history
of multiple failures, presenting with a broad spectrum
of HIV resistance mutations, or multiple intolerances or
contraindications to other antiretroviral drugs and com-
binations [39].
Appendix : the EuroSIDA Study Group
Members of the multi-centre EuroSIDA Study Group
are as follows (national coordinators in parentheses).
Argentina: (M. Losso) and M. Kundro, Hospital J.M.
Ramos Mejia, Buenos Aires. Austria: (B. Schmied), Pul-
mologisches Zentrum der Stadt Wien, Vienna; R. Zan-
gerle, Medical University Innsbruck, Innsbruck. Belarus:
(I. Karpov) and A. Vassilenko, Belarus State Medical
University, Minsk; V. M. Mitsura, Gomel State Medical
University, Gomel; D. Paduto, Regional AIDS Centre,
Svetlogorsk. Belgium: (N. Clumeck), S. De Wit and M.
Delforge, Saint-Pierre Hospital, Brussels; E. Florence,
Institute of Tropical Medicine, Antwerp; L. Vandekerck-
hove, University Ziekenhuis Gent, Gent. Bosnia-
Herzegovina: (V. Hadziosmanovic), Klinicki Centar
Univerziteta Sarajevo, Sarajevo. Croatia: (J. Begovac),
University Hospital of Infectious Diseases, Zagreb. Czech
Republic: (L. Machala) and D. Jilich, Faculty Hospital
Bulovka, Prague; D. Sedlacek, Charles University Hospi-
tal, Plzen. Denmark: G. Kronborg and T. Benfield, Hvi-
dovre Hospital, Copenhagen; J. Gerstoft and T.
Katzenstein, Rigshospitalet, Copenhagen; N. F. Møller
and C. Pedersen, Odense University Hospital, Odense; L.
Ostergaard, Skejby Hospital, Aarhus; L. Wiese, Roskilde
Hospital, Roskilde; L. N. Nielsen, Hillerod Hospital,
Hillerod. Estonia: (K. Zilmer), West-Tallinn Central
Hospital, Tallinn; J. Smidt, Nakkusosakond Siseklinik,
Kohtla-J€arve. Finland: (M. Ristola) and I. Aho, Helsinki
University Central Hospital, Helsinki. France: (J.-P.
Viard), Ho^tel-Dieu, Paris; P.-M. Girard, Hospital Saint-
Antoine, Paris; C. Pradier and E. Fontas, Ho^pital de
l’Archet, Nice; C. Duvivier, Ho^pital Necker-Enfants
Malades, Paris. Germany: (J. Rockstroh), Universit€ats
Klinik Bonn, Bonn; R. Schmidt, Medizinische
Hochschule Hannover, Hannover; O. Degen, University
Medical Center Hamburg-Eppendorf, Infectious Diseases
Unit, Hamburg; H. J. Stellbrink, IPM Study Center,
Hamburg; C. Stefan, JW Goethe University Hospital,
Frankfurt; J. Bogner, Medizinische Poliklinik, Munich;
G. F€atkenheuer, Universit€at K€oln, Cologne. Georgia: (N.
Chkhartishvili), Infectious Diseases, AIDS & Clinical
Immunology Research Center, Tbilisi. Greece: P. Gar-
galianos, G. Xylomenos and P. Lourida, Athens General
Hospital, Athens; H. Sambatakou, Ippokration General
Hospital, Athens. Hungary: (J. Szlavik), Szent Laslo
Hospital, Budapest. Iceland: (M. Gottfredsson), Landspi-
tali University Hospital, Reykjavik. Ireland: (F. Mulc-
ahy), St. James’s Hospital, Dublin. Israel: (I. Yust), D.
Turner and M. Burke, Ichilov Hospital, Tel Aviv; E.
Shahar and G. Hassoun, Rambam Medical Center,
Haifa; H. Elinav and M. Haouzi, Hadassah University
Hospital, Jerusalem; D. Elbirt and Z. M. Sthoeger, AIDS
Center (Neve Or), Jerusalem. Italy: (A. D’Arminio Mon-
forte), Istituto Di Clinica Malattie Infettive e Tropicale,
Milan; R. Esposito, I. Mazeu and C. Mussini, Universita
Modena, Modena; F. Mazzotta and A. Gabbuti, Ospedale
S. Maria Annunziata, Firenze; V. Vullo and M. Licht-
ner, University di Roma la Sapienza, Rome; M. Zac-
carelli, A. Antinori, R. Acinapura and M. Plazzi, Istituto
Nazionale Malattie Infettive Lazzaro Spallanzani, Rome;
A. Lazzarin, A. Castagna and N. Gianotti, Ospedale San
Raffaele, Milan; M. Galli and A. Ridolfo, Osp. L. Sacco,
Milan. Latvia: (B. Rozentale), Infectology Centre of Lat-
via, Riga. Lithuania: (V. Uzdaviniene), Vilnius Univer-
sity Hospital Santariskiu Klinikos, Vilnius; R.
Matulionyte, Center of Infectious Diseases, Vilnius
University Hospital Santariskiu Klinikos, Vilnius. Lux-
embourg: (T. Staub) and R. Hemmer, Centre Hospitalier,
Luxembourg. The Netherlands: (P. Reiss), Academisch
Medisch Centrum bij de Universiteit van Amsterdam,
Amsterdam. Norway: (V. Ormaasen), A. Maeland and J.
Bruun, Ulleval Hospital, Oslo. Poland: (B. Knysz), J.
Gasiorowski and M. Inglot, Medical University, Wro-
claw; A. Horban and E. Bakowska, Centrum Diagnostyki
i Terapii AIDS, Warsaw; R. Flisiak and A. Grzeszczuk,
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Medical University, Bialystok; M. Parczewski, K.
Maciejewska and B. Aksak-Was, Medical Univesity,
Szczecin; M. Beniowski and E. Mularska, Osrodek Diag-
nostyki i Terapii AIDS, Chorzow; T. Smiatacz and M.
Gensing, Medical University, Gdansk; E. Jablonowska,
E. Malolepsza and K. Wojcik, Wojewodzki Szpital Spec-
jalistyczny, Lodz; I. Mozer-Lisewska, Poznan University
of Medical Sciences, Poznan. Portugal: (L. Caldeira),
Hospital Santa Maria, Lisbon; K. Mansinho, Hospital de
Egas Moniz, Lisbon; F. Maltez, Hospital Curry Cabral,
Lisbon. Romania: (R. Radoi) and C. Oprea, Spitalul de
Boli Infectioase si Tropicale: Dr. Victor Babes, Bucarest.
Russia: (A. Panteleev) and O. Panteleev, St Petersburg
AIDS Centre, St Petersburg; A. Yakovlev, Medical Acad-
emy Botkin Hospital, St Petersburg; T. Trofimora, Nov-
gorod Centre for AIDS, Novgorod; I. Khromova, Centre
for HIV/AIDS and Infectious Diseases, Kaliningrad; E.
Kuzovatova, Nizhny Novgorod Scientific and Research
Institute of Epidemiology and Microbiology named after
Academician I. N. Blokhina, Nizhny Novogrod; E. Boro-
dulina and E. Vdoushkina, Samara State Medical
University, Samara. Serbia: (D. Jevtovic), The Institute
for Infectious and Tropical Diseases, Belgrade. Slovenia:
(J. Tomazic), University Clinical Centre Ljubljana, Ljubl-
jana. Spain: (J. M. Gatell) and J. M. Miro, Hospital
Clinic Universitari de Barcelona, Barcelona; S. Moreno
and J. M. Rodriguez, Hospital Ramon y Cajal, Madrid;
B. Clotet, A. Jou, R. Paredes, C. Tural, J. Puig and I.
Bravo, Hospital Germans Trias i Pujol, Badalona; P.
Domingo, M. Gutierrez, G. Mateo and M. A. Sambeat,
Hospital Sant Pau, Barcelona; J. M. Laporte, Hospital
Universitario de Alava, Vitoria-Gasteiz.
Sweden: (K. Falconer), A. Thalme and A. Sonnerborg,
Karolinska University Hospital, Stockholm; A. Blaxhult,
Venh€alsan-Sodersjukhuset, Stockholm; L. Flamholc,
Malm€o University Hospital, Malm€o. Switzerland: (A.
Scherrer) and R. Weber, University Hospital Zurich, Zur-
ich; M. Cavassini, University Hospital Lausanne, Lau-
sanne; A. Calmy, University Hospital Geneva, Geneva; H.
Furrer, University Hospital Bern, Bern; M. Battegay,
University Hospital Basel, Basel; P. Schmid, Cantonal
Hospital St. Gallen, St. Gallen. Ukraine: A. Kuznetsova,
Kharkov State Medical University, Kharkov; G. Kyselyova,
Crimean Republican AIDS Centre, Simferopol; M.
Sluzhynska, Lviv Regional HIV/AIDS Prevention and
Control CTR, Lviv. UK: (B. Gazzard), St. Stephen’s Clinic,
Chelsea and Westminster Hospital, London; A. M. John-
son, E. Simons and S. Edwards, Mortimer Market Centre,
London; A. Phillips, M. A. Johnson and A. Mocroft, Royal
Free and University College Medical School (Royal Free
Campus), London; C. Orkin, Royal London Hospital, Lon-
don; J. Weber and G. Scullard, Imperial College School of
Medicine at St. Mary’s, London; A. Clarke, Royal Sussex
County Hospital, Brighton; C. Leen, Western General
Hospital, Edinburgh.
The following centres have previously contributed
data to EuroSIDA: Infectious Diseases Hospital, Sofia,
Bulgaria; Ho^pital de la Croix Rousse, Lyon, France;
Ho^pital de la Pitie-Salpetiere, Paris, France; Unite
INSERM, Bordeaux, France; Ho^pital Edouard Herriot,
Lyon, France; Bernhard Nocht Institut f€ur Tropenmedi-
zin, Hamburg, Germany; 1st I.K.A Hospital of Athens,
Athens, Greece; Ospedale Riuniti, Divisione Malattie
Infettive, Bergamo, Italy; Ospedale di Bolzano, Divisione
Malattie Infettive, Bolzano, Italy; Ospedale Cotugno, III
Divisione Malattie Infettive, Napoli, Italy; Derer Hospi-
tal, Bratislava, Slovakia; Hospital Carlos III, Departa-
mento de Enfermedades Infecciosas, Madrid, Spain;
Kiev Centre for AIDS, Kiev, Ukraine; Luhansk State
Medical University, Luhansk, Ukraine; Odessa Region
AIDS Center, Odessa, Ukraine.
EuroSIDA Steering Committee
Steering Committee: J. Gatell, B. Gazzard, A. Horban, I.
Karpov, M. Losso, A. d’Arminio Monforte, C. Pedersen, M.
Ristola, A. Phillips, P. Reiss, J. Lundgren and J.
Rockstroh.
Chair: J. Rockstroh.
Study Co-leads: A. Mocroft and O. Kirk.
EuroSIDA representatives to EuroCoord: O. Kirk, A.
Mocroft, P. Reiss, A. Cozzi-Lepri, R. Thiebaut, J.
Rockstroh, D. Burger, R. Paredes and L. Peters.
EuroSIDA staff
Coordinating Centre staff: O. Kirk, L. Peters, C. Matthews,
A. H. Fischer, A. Bojesen, D. Raben, D. Kristensen, K.
Grønborg Laut, J. F. Larsen and D. Podlekareva.
Statistical staff: A. Mocroft, A. Phillips, A. Cozzi-Lepri,
L. Shepherd, A. Schultze and S. Amele.
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Please find the SOP for identifying coauthors in the Euro-
SIDA Study at http://www.chip.dk/Portals/0/files/Euro
sida/EuroSIDA/SOP%20coauthorship.pdf?timestamp=
1464082845266.
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Please find the criteria for participating in the EuroSIDA
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